Bayesian Analysis CEA

Concept

Theoretically, Bayesian Analysis in Cost-Effectiveness Analysis (CEA) is a probabilistic framework that combines prior evidence with observed data to estimate the joint posterior distribution of costs, health outcomes and cost-effectiveness. It is founded on Bayes' theorem and Bayesian decision theory, allowing uncertainty from multiple evidence sources to be incorporated directly into economic evaluation. In health economics, Bayesian analysis is widely applied to parameter estimation, evidence synthesis, probabilistic sensitivity analysis and decision-making under uncertainty.

Mathematically, Bayesian cost-effectiveness analysis updates prior probability distributions using observed evidence to obtain posterior distributions for model parameters. Posterior samples are propagated through the economic model to estimate expected costs, expected health outcomes, incremental cost-effectiveness ratios, net monetary benefit and the probability that an intervention is cost-effective at different willingness-to-pay thresholds. Estimation is typically performed using Markov chain Monte Carlo (MCMC) methods.

In practice, Bayesian analysis is implemented by specifying prior distributions, constructing likelihood functions from available evidence, estimating posterior parameter distributions and propagating posterior uncertainty through probabilistic economic models. It is routinely used in health technology assessment, network meta-analysis and complex decision models where multiple sources of uncertainty must be quantified simultaneously.

---

Purpose

Used to combine prior evidence with observed data, quantify parameter uncertainty, estimate posterior cost-effectiveness and support probabilistic decision-making in health economic evaluation.

---

Mathematical Formulae

Primary Formula

P(?|D) = [P(D|?) ? P(?)] / P(D)

Where:

P(?|D) = posterior distribution

P(D|?) = likelihood

P(?) = prior distribution

P(D) = marginal likelihood

Supporting Formulae

Expected Net Monetary Benefit:

E(NMB) = E(?E ? C)

Posterior expected incremental net monetary benefit:

E(INMB|D) = ?E(?E|D) ? E(?C|D)

Probability of cost-effectiveness:

Pr(NMB > 0 | D)

Related Mathematical Methods

• Bayes' theorem
• Markov chain Monte Carlo
• Bayesian hierarchical modelling
• Bayesian network meta-analysis
• Probabilistic sensitivity analysis
• Net monetary benefit analysis

---

Example

A health technology assessment evaluates a new oncology treatment using prior evidence from previous studies and data from a new randomised trial. Bayesian updating produces posterior estimates of incremental costs and QALYs. Posterior simulation estimates a mean incremental cost of �9,200 and a mean incremental benefit of 0.48 QALYs. At a willingness-to-pay threshold of �30,000 per QALY, the posterior expected incremental net monetary benefit is:

INMB = (30,000 ? 0.48) ? 9,200 = �5,200

Posterior simulation indicates a 91% probability that the intervention is cost-effective.

---

Excel Implementation

Function	Example Formula	Health Economics Application
NORM.DIST	=NORM.DIST(A2,Mean,SD,FALSE)	Evaluates likelihoods or prior distributions under normal assumptions.
RAND	=RAND()	Generates random values for posterior simulation.
AVERAGE	=AVERAGE(PosteriorRange)	Estimates posterior expected costs or QALYs.
COUNTIF	=COUNTIF(NMBRange,">0")/COUNT(NMBRange)	Estimates the posterior probability that an intervention is cost-effective.

---

VBA (Optional)

VBA can automate posterior simulation, probabilistic sensitivity analysis and generation of Bayesian cost-effectiveness summaries from Monte Carlo samples.

---

Sources

Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press; 2006.

Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley; 2004.

Gelman A, Carlin JB, Stern HS, et al. Bayesian Data Analysis. 3rd ed. CRC Press; 2013.

ISPOR-SMDM Modeling Good Research Practices Task Force. Model Parameter Estimation and Uncertainty Analysis.

NICE. Health Technology Evaluations: The Manual. National Institute for Health and Care Excellence; 2022.